About

Welcome to the Collaborative Adverse Outcome Pathway Wiki (AOP-Wiki)


Background

If you are interested in contributing AOP-related knowledge to the AOP-KB, please follow the instructions laid out at the OECD Adverse Outcome Pathways, Molecular Screeing and Toxicogenomics page. The Guidance on Developing and ASsessing AOPs document is the basis for all work related to contributing and sharing AOP-related knowledge. A Users' Handbook Supplement to this Gudance has been written to aid systematic development and transparent assessment of Adverse Outcome Pathways (AOPs). That handbook contains a template to guide AOP description and provides focused and practical instructions for develpers and assessors indended to assist in identifying, organizing, and evaluating critical information on key events and linkages (i.e., key event relationships (KER)) with the AOP, as well as guidance on how to assess the weight of evidence supporting the overall AOP.

This wiki represents a joint effort between the European Commision - DG Joint Research Centre (JRC)and U.S Environmental Protection Agency (EPA). This serves as one component of a larger OECD-sponsored AOP Knowledgebase effort and represents the central repository for all AOPs developed as part of the OECD AOP Development Effort by the Extended Advisory Group on Molecular Screening and Toxicogenomics. The other major components of this knowledgebase are Effectopedia, produced by the Organisation for Economic Co-operation and Development (OECD), the AOP Xplorer, produced by the US Army Corps of Engineers - Engineering Research and Development Center, and the Intermediate Effects DB produced by the JRC.

This wiki is based upon the Chemical Mode of Action wiki developed by the EPA under the auspices of the WHO International Programe on Chemical Safety (IPCS) Mode of Action Steering Group.

Disclaimer

The content of this wiki is the sole responsibility of the individual contributors and does not necessarily represent the views of the Partner organizations. Mention of trade names or commercial products does not constitute endorsement by any of the Partner organizations.